mike bonney

Third Rock Ventures Names Industry Leader Michael W. Bonney as Partner

Read More

Take a look at what we’ve been up to for the past 8+ years

Watch the Video

Nurix enters strategic collaboration with Celgene focused on immune-oncology

Read More

Revolution Medicines Featured in Chemical & Engineering News’ List of the Top Startups to Watch of 2015

Read More

Check out Nurix and Afferent Featured in Forbes’ Hottest Startups of 2015

Read More

Partner Profile: Neil Exter

Read More

Decibel Therapeutics Launches with $52 million to Discover New Medicines to Protect, Repair and Restore Hearing

Read More

Congrats to partner Mark Levin for being recognized on BBJ's Power 50 list

Read More

Immuno-oncology Company Neon Therapeutics Launches With $55M Series A Financing

Read More

Congrats to our Fierce 15 winners!

Read More

Sign up for weekly portfolio company news alerts here
 

Read More

Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock

Watch the Video

Transforming Healthcare

37

Portfolio Companies
With More Than $1.3 Billion
Under Management

45

Clinical Studies
Underway Within Our Portfolio

60

Diseases
Being Targeted By
Our Companies

10  

of thousands

Patients Impacted
By Portfolio Company Products
and Clinical Trials